COLL Stock Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for COLL from our risk checks.
My Notes
NewNotes are coming soon
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$28.29 |
52 Week High | US$30.22 |
52 Week Low | US$14.04 |
Beta | 0.74 |
1 Month Change | 21.94% |
3 Month Change | 57.69% |
1 Year Change | 61.84% |
3 Year Change | 40.64% |
5 Year Change | 25.18% |
Change since IPO | 130.19% |
Recent News & Updates
Recent updates
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment
May 14Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings
May 13We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt
May 01Read This Before Judging Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE
Feb 20Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jan 16Collegium Pharmaceutical (NASDAQ:COLL) Share Prices Have Dropped 27% In The Last Five Years
Dec 12Shareholder Returns
COLL | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.6% | -1.4% | 2.8% |
1Y | 61.8% | 4.5% | -9.2% |
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: COLL exceeded the US Market which returned -9.2% over the past year.
Price Volatility
COLL volatility | |
---|---|
COLL Average Weekly Movement | 6.8% |
Pharmaceuticals Industry Average Movement | 11.1% |
Market Average Movement | 6.9% |
10% most volatile stocks in US Market | 17.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: COLL's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 152 | Joe Ciaffoni | https://www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
COLL fundamental statistics | |
---|---|
Market Cap | US$949.75m |
Earnings (TTM) | -US$42.84m |
Revenue (TTM) | US$361.68m |
2.6x
P/S Ratio-22.2x
P/E RatioIs COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COLL income statement (TTM) | |
---|---|
Revenue | US$361.68m |
Cost of Revenue | US$68.78m |
Gross Profit | US$292.90m |
Other Expenses | US$335.73m |
Earnings | -US$42.84m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.28 |
Gross Margin | 80.98% |
Net Profit Margin | -11.84% |
Debt/Equity Ratio | 366.9% |
How did COLL perform over the long term?
See historical performance and comparison